Approaches to metastatic skin melanoma therapy in 2020: a dynamic way forward

The choice of first-line therapy for metastatic skin melanoma has become quite a difficult task in the last few years: a practicing oncologist has got drugs of different classes with different mechanisms of action – immune checkpoint blockers and BRAF/MEK tyrosine kinase inhibitors. In this study, t...

Popoln opis

Bibliografske podrobnosti

Principais autores:	I. V. Samoylenko, L. V. Demidov
Format:	Artigo
Jezik:	Russo
Izdano:	Remedium Group LLC 2020-07-01
Serija:	Медицинский совет
Teme:	metastatic melanoma prognosis biomarkers first line of therapy combined immunotherapy monotherapy with immune checkpoints blockers combined targeting therapy triple combination of brafi + meki + apdl1 reversion to previous therapy (re-challenge)
Online dostop:	https://www.med-sovet.pro/jour/article/view/5707
Oznake:	Označite Brez oznak, prvi označite!